North America preventive vaccines market is projected to grow by 6.3% annually in the forecast period and reach $46.90 billion by 2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines such as COVID-19 vaccines, and the increasing healthcare expenditure.
Highlighted with 52 tables and 51 figures, this 132-page report "North America Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity" is based on a comprehensive research of the entire North America preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter's Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify North America preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.
Based on Vaccine Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• mRNA Vaccines
• Recombinant Vector Vaccines
• Other Vaccines
Based on Disease, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Pneumococcal Disease
• Poliovirus
• Hepatitis
• Influenza
• Measles, Mumps, and Rubella (MMR)
• Varicella
• Human Papilloma Virus
• COVID-19
• Other Diseases
By Administration, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Intramuscular Route
• Subcutaneous Route
• Oral Route
• Intravenous Injection
• Other Administration Routes
By Patient, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Pediatric Vaccines
o Pneumococcal
o Measles, Mumps, and Rubella (MMR)
o Varicella
o Hepatitis
o Poliovirus
o Haemophilus Influenzae B (HIB)
o Other Diseases
• Adult Vaccines
o Influenza
o Cervical Cancer
o Hepatitis
o Zoster
o Other Diseases
Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each key country, detailed analysis and annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Vaccine Type, Disease, and Administration over the forecast years are also included.
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
1 Introduction 8
1.1 Industry Definition and Research Scope 8
1.1.1 Industry Definition 8
1.1.2 Research Scope 9
1.2 Research Methodology 12
1.2.1 Overview of Market Research Methodology 12
1.2.2 Market Assumption 13
1.2.3 Secondary Data 13
1.2.4 Primary Data 13
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 25
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 27
2.2 Major Growth Drivers 31
2.3 Market Restraints and Challenges 37
2.4 Emerging Opportunities and Market Trends 40
2.5 Porter's Fiver Forces Analysis 44
3 Segmentation of North America Market by Vaccine Type 48
3.1 Market Overview by Vaccine Type 48
3.2 Live/Attenuated Vaccines 50
3.3 Inactivated Vaccines 51
3.4 Subunit Vaccines 52
3.5 Toxoid Vaccines 53
3.6 Conjugate Vaccines 54
3.7 mRNA Vaccines 55
3.8 Recombinant Vector Vaccines 56
3.9 Other Vaccines 57
4 Segmentation of North America Market by Disease 58
4.1 Market Overview by Disease 58
4.2 Pneumococcal Disease 60
4.3 Poliovirus 61
4.4 Hepatitis 62
4.5 Influenza 63
4.6 Measles, Mumps, and Rubella (MMR) 64
4.7 Varicella 65
4.8 Human Papilloma Virus 66
4.9 COVID-19 67
4.10 Other Diseases 68
5 Segmentation of North America Market by Administration 69
5.1 Market Overview by Administration 69
5.2 Intramuscular Route 71
5.3 Subcutaneous Route 72
5.4 Oral Route 73
5.5 Intravenous Injection 74
5.6 Other Administration Routes 75
6 Segmentation of North America Market by Patient 76
6.1 Market Overview by Patient 76
6.2 Pediatric Vaccines 78
6.3 Adult Vaccines 80
7 North America Market 2022-2032 by Country 82
7.1 Overview of North America Market 82
7.2 U.S. 85
7.3 Canada 89
7.4 Mexico 92
8 Competitive Landscape 95
8.1 Overview of Key Vendors 95
8.2 New Product Launch, Partnership, Investment, and M&A 98
8.3 Company Profiles 99
AstraZeneca plc 99
Bavarian Nordic A/S 101
China National Biotec Group Company Ltd. 104
CSL Ltd. 106
Daiichi Sankyo Co. Ltd 108
Emergent BioSolutions Inc. 110
GlaxoSmithKline plc 112
Johnson & Johnson 116
Merck & Co. 118
Moderna Inc. 120
Novavax, Inc. 121
Pfizer Inc. 123
Sanofi SA 127
Takeda Pharmaceutical Co. Ltd. 130
RELATED REPORTS 132
Market Overview
The North America Vanadium Market is expected to experience substantial growth from 2024 to 2034, driven by increasing demand from various sectors such as iron and steel, energy storage, and chemicals. The market is projected to grow from USD XXX.XX million in 2024 to US...
Market Overview
The North America Vascular Closure Devices (VCD) Market is anticipated to witness significant growth from 2024 to 2034, driven by the increasing volume of minimally invasive cardiovascular procedures, rising prevalence of cardiovascular diseases, and advancements in vasc...
Market Overview
The North America Nuclear Medicine Market is poised for substantial growth between 2024 and 2034, driven by advancements in diagnostic imaging and therapeutic applications, rising prevalence of chronic diseases, and increasing adoption of nuclear medicine techniques. The...
Market Overview
The North America Anti-Pollution Mask Market is anticipated to witness significant growth from 2024 to 2034, driven by increasing awareness of air quality issues and the rising prevalence of respiratory diseases. The market, encompassing a wide range of anti-pollution ma...
Market Overview
The North America Ethnic Wear Market is set to experience considerable growth from 2024 to 2034, driven by evolving fashion trends and a growing appreciation for cultural heritage. The market, which includes a diverse range of ethnic apparel, is projected to reach USD XX...
Market Overview
The North America FinTech Investment Market is set to experience substantial growth from 2024 to 2034, driven by an accelerated adoption of innovative financial technologies across various sectors. The market, which encompasses investments in a wide range of FinTech solu...
Market Overview
The North America Airport Asset Tracking Market is set for significant growth from 2024 to 2034, driven by advancements in asset tracking technologies and increased focus on operational efficiency and safety within airport environments. The market is projected to grow fr...
Market Overview
The North America Sustainable Aviation Fuel Market is projected to experience robust growth from 2024 to 2034, driven by increasing environmental regulations, rising focus on reducing carbon emissions in aviation, and advancements in alternative fuel technologies. By 203...
Market Overview
The North America Integrated Facility Management (IFM) Market is projected to experience significant growth from 2024 to 2034, driven by the increasing demand for comprehensive facility management solutions across various industries. As organizations seek to optimize ope...
Market Overview
The North America Smart Air Conditioner Market is poised for substantial growth from 2024 to 2034, driven by advancements in technology and increasing consumer demand for energy-efficient and intelligent climate control solutions. Smart air conditioners, known for their ...